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Background: Tuberculosis (TB) remains as a major cause of death. Construction 
of a new vaccine against tuberculosis is an effective way to control it. Several vaccines 
against this disease have been developed. The aim of the present study was to cloning 
of tb10.4 gene in pcDNA3.1+ plasmid and evaluation of its expression in eukaryotic 
cells.  
Methods: Firstly, tb10.4 fragment was amplified by PCR and the PCR product 
was digested with restriction enzymes. Next, it was cloned into pcDNA3.1+ plasmid. 
Following that, pcDNA3.1+/tb10.4 recombinant plasmid was transfected into 
eukaryotic cells.  
Results: 5700 bp band for pcDNA3.1+/tb10.4 recombinant plasmid and 297 bp 
fragment for tb10.4 were observed. Cloning and transfection were successful and 
designed recombinant vector was confirmed by sequencing.
Conclusion: Successful cloning provides a basis for the development of new DNA 
vaccines against tuberculosis.
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Introduction
In 1882, Robert Koch isolated and identified 
Mycobacterium tuberculosis as the cause of tu-
berculosis (1). M. tuberculosis, the causative 
agent of TB, is a common pathogen that has not 
been controlled effectively in many parts of the 
world (2).
TB is a major cause of mortality with almost 
3 million people death each year (3). Our ability 
to control and in some cases eradicate human dis-
ease caused by pathogenic bacteria and viruses 
has been improved by the capacity to stimulate 
protective immunity by vaccinating susceptible 
hosts with attenuated or inactivated bacteria (4).
In 1992, Tang et al. showed that injection of 
DNA could induce immune responses (5). It was 
later reported that DNA vaccines induce protec-
tive immunity in several animal models of par-
asitic, viral and bacterial infections. DNA vac-
cines have advantages over other vaccines (6).
The only vaccine permitted by the WHO for 
human use in cases of TB is BCG (2, 4, 7). Ac-
cording to the routine immunization program, 
this vaccine is injected at birth or after the first 
contact with M. tuberculosis (2). While infant 
vaccination with BCG vaccine has been effective 
to reduce the severe form of childhood tubercu-
losis in endemic areas, its protective effects de-
creases with time (lasts fewer than 15 yr). This 
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results in highly variable efficiency, which seems 
insufficient to control pulmonary tuberculosis 
among adults (2, 4, 8, 9).
The efficacy limitation of BCG vaccine is a 
motivating force for the development new and 
better vaccines against tuberculosis (2, 4). These 
include plasmid DNA vaccines encoding domi-
nant genes of M. tuberculosis, recombinant BCG 
vaccine, attenuated M. tuberculosis, and recom-
binant protein antigens subunit vaccines (3).
Among the new vaccine platforms, genetic 
vectors such as recombinant plasmid DNA vec-
tors have widely been used to deliver micro-
bial antigen-coding genes. These vectors could 
strongly induce both CD4+ and CD8+ T cell re-
sponses, required for effective TB vaccination 
(10).
The gene encoding TB10.4 belongs to a 
subfamily of the ESAT-6 family that encoded 
three homologous proteins including TB10.4 
(Rv0288), TB10.3 (Rv3019c) and TB12.9 
(Rv3017c). These three members are only pres-
ent in some strains of M. tuberculosis complex 
including BCG and M. kansasii (1).
Time (second) Temperature (˚C) Cycle
300 95 1
60 95
4060 52
60 72
420 72 1
Table 1
PCR Program for tb10.4
The aim of the present study was cloning of 
tb10.4 gene in pcDNA3.1+ plasmid and evalua-
tion of its expression in eukaryotic cells.
Materials and Methods
This study was performed at Mashhad Uni-
versity of Medical Sciences (Mashhad, Iran) 
from April 2012 to March 2013.
DNA extraction
To extract DNA, M. tuberculosis H37Rv strain 
(Pasteur Institute, Tehran, Iran) was used. Some 
of the bacteria grown in Middle Brook medium 
were transferred into Lewen Stein Johnson me-
dium. After that, the medium was incubated at 37 
°C until colonies formed. After that, their DNA 
was extracted with Tris/Tween20 method (11).
Amplification of tb10.4 fragment
To amplify tb10.4 fragment with PCR meth-
od, two primers were used, 5ʹ-ATATATAGAAT
TCTCGCAAATCATGTACAAC-3ʹ as forward 
primer and 5ʹ-ACTATATCTAGATTACTAAC
CTCCCCATTTGGCG–3ʹ as reverse primer (in 
forward and reverse primers, the underlined let-
ters, respectively, indicates positions of EcoRI 
and XbaI restriction enzyme restriction sites.
PCR reaction mixture contains 1μl DNA 
(100 ng/μl), 0.5μl dNTP (0.2 mM), 0.3μl Taq 
DNA polymerase enzyme (5U/ml), 1.5ml MgCl2 
(1.5mM), 2.5μl 10X Buffer (Fermentas, Germa-
ny), 17.2μl DNase free water, 1μl Forward prim-
er (10 pmol) and 1μl reverse primer (10 pmol) 
(CinnaGen, Iran).  PCR program was as follows 
(Table 1).
Cloning of tb10.4 fragment in pcDNA3.1+ vector
Fifty micro liters of the PCR product was used 
for electrophoresis in 1.5% agarose gel. Purifi-
cation of gel was performed using Invitek DNA 
extraction kit (California, USA). For tb10.4 
enzymatic digestion, a mixture containing 5 μl 
XbaI (50U/μl), 4 μl EcoRI (10U/μl) and 5 μl 
10X Buffer H (Fermentas, Germany) was mixed 
in one micro tube and 20 μl tb10.4 was added 
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to it (total volume was increased to 50 μl using 
DNase free water) and then were incubated at 37 
˚C for 16 h. PcDNA3.1+ plasmid was extracted 
with alkaline method. In this method, plasmid 
DNA was sedimented with different solutions. It 
was then extracted by washing with isopropanol. 
The extracted plasmid DNA was purified with 
Invitek DNA extraction kit (California, USA). 
For pcDNA3.1+ enzymatic digestion, a mixture 
containing 5 μl XbaI (50U/μl), 4 μl EcoRI (10U/
μl) and 5 μl 10X Buffer H (Fermentas, Germany) 
was mixed in one micro tube. Following that, 
10μl pcDNA3.1+ plasmid was added in it (total 
volume was increased to 50 μl using DNase free 
water) and was then incubated at 37 ˚C for 16 
h. In the next step, digested and purified tb10.4 
fragments, were ligated to purified pcDNA3.1+ 
plasmid using T4 DNA ligase restriction enzyme 
(Fermentas, Germany). Ligation mixture con-
tained 2 μl PEG, 2 μl T4 DNA ligase (5U/μl), 
2.5 μl T4 DNA ligase 10X buffer (Fermentas, 
Germany), 12 μl tb10.4 DNA (25 ng/μl), 6 μl 
pcDNA3.1+ plasmid (100ng/μl) and 0.5 μl DN-
ase free water. It was incubated at 22 ˚C for 16 h.
Competent E. coli bacteria strain JM109, was 
prepared using CaCl2 0.5 M and pcDNA3.1+/
tb10.4 plasmid was transferred into competent 
bacteria using heat shock method (12). 
Confirmed tb10.4 cloning in pcDNA3.1+ vector
Transformed bacteria were inoculated on LB 
agar medium containing 100 µg/µl ampicillin and 
were incubated for 16h at 37 °C. Cloning Tb10.4 
gene in pcDNA3.1+ vector was confirmed by 
colony-PCR method (using tb10.4 specific prim-
ers) and enzymatic digestion with EcoRI restric-
tion enzyme. 
HeLa cell culture
Eukaryotic HeLa cell was cultured in DMEM 
medium, which contained 10% fetal bovine se-
rum (FBS), and 1% antibiotics and then incu-
bated in 37 °C until the cells begin to grow and 
proliferation.
Transfection in eukaryotic cells
pcDNA3.1+/tb10.4 recombinant plasmid was 
purified with alkaline method and transfected 
in eukaryotic HeLa cell with cationic liposome 
method using lipofectamine.
To confirm tb10.4 gene expression, 48 h after 
transfection, the medium of cells were collected 
and used for RNA extraction.
RNA extraction and cDNA synthesis
RNA extraction was performed 
with RNX-PLUS kit according to the 
recommendations (CinnaGen, Iran). To remove 
the transfected vector, extracted RNA was di-
gested by enzymatic digestion with DNaseI. 
Then, cDNA synthesis was performed with oligo 
dT primers kit (Invitrogen, San Di- ego, Califor-
nia).
Confirming the expression of tb10.4 fragment
To confirm the expression of tb10.4 fragment, 
PCR method was used using tb10.4 specific 
primers as described at first in amplification of 
tb10.4 fragment section.
Results
The extracted DNA was further used for PCR 
with specific primers. PCR products were sub-
jected for electrophoresis on a 1.5% agarose gel, 
and 290 bp fragment of tb10.4 gene was observed 
(Figure 1).
After purification of tb10.4 products, they 
were digested with restriction enzymes. This 
fragment was further ligated to a pcDNA3.1+ 
plasmid and was transformed into a competent 
E. coli JM109 strain. 
After 16 h of transformation of competence 
bacteria and incubation at 37 °C, some colonies 
were grown on LB agar medium containing am-
tb10.4 DNA vaccine encoding for M. tuberculosis 
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picillin. The pcDNA3.1+/tb10.4 recombinant 
vector was confirmed by colony- PCR using 
specific primers of tb10.4. Colonies with the spe-
cific plasmid were positive and showed the cor-
responding 290 bp size marker.
Results of the enzymatic digestion showed 
tb10.4 fragment ligated in pcDNA3.1+ plasmid 
(Figure 2). Recombinant pcDNA3.1+/tb10.4 was 
transfected into HeLa eukaryotic cell (grown on a 
DMEM medium culture) and cells incubated for 
48 h at 37 °C. Finally, to confirm the expression 
of this gene in eukaryotic cells, RNA extraction, 
cDNA synthesis and RT-PCR were performed 
with a 290 bp fragment of tb10.4 gene (Figure 3).
Discussion
Fig. 1
PCR result for tb10.4. Lane 1: PCR products of a 290bp 
amplified fragment of tb10.4 gene M: 1kb DNA size 
marker (SM0313, Fermentas, Germany). 
Fig. 3
Enzymatic digestion of pcDNA3.1+/tb10.4 plasmid with 
EcoRI and XbaI restriction enzymes. Lane M: 1kb DNA 
size marker (SM0313, Fermentas, Germany). Lane 1: 
5700 bp band of pcDNA3.1+/tb10.4 recombinant plasmid 
digested with EcoRI. Lane 2: 5400 bp band of pcDNA3.1+ 
plasmid digested with EcoRI and XbaI.
Fig. 2
RT-PCR results. Lane M: 1kb DNA size marker (SM0313, 
Fermentas, Germany). Lane 1: 290 bp fragment of tb10.4 
gene in RT-PCR.
One of the World Health Organization Mil-
lennium Development Goal is to reduce tuber-
culosis incidence by 2015. By designing and de-
velopment of more effective drugs and vaccines 
compared to the conventional BCG (as currently 
being the only available vaccine), WHO target of 
decreasing the incidence of tuberculosis can be 
reached (9).
Since the completion of whole-genome se-
quencing of the causative agent M. tuberculosis, 
more than 100 DNA vaccines have been studied 
in animal TB models but still protective antigen 
for tuberculosis is not clear and this has created a 
major impediment to the development of tuber-
culosis vaccines (13).
In the past, many secreted proteins of M. tu-
berculosis were considered as candidate vaccines 
against tuberculosis. However, not all vaccines 
encoding antigens of M. tuberculosis were effec-
tive. Some plasmid DNAs encoding genes, such 
as 19 kDa lipoprotein, AhpC or crystalline alpha, 
rather than stimulating T-cell responses against 
the protein, were only able to stimulate non-pro-
tective antibody responses (13). 
Another plasmid DNAs encoding 22 kDa pro-
tein, Pst-1 or HBHA of M. tuberculosis, provides 
no protection. Nevertheless, they could stimu-
Rashidian et al.
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late the antigen-specific antibody response and 
Th1-type immune response. So far, only a few 
DNA vaccine, encoding ag85a, ag85b, esat-6, 
pst-3 and hsp65 have shown promising degree of 
protection in mouse models. Therefore, they are 
possible candidate proteins for developing tuber-
culosis vaccines (13).TB10.4 is a recently identi-
fied protein encoded by the Rv0288 gene located 
in the esx cluster 3. TB10.4 appears to be essen-
tial for the virulence of M. tuberculosis (14, 15). 
The expression of Rv0288 is significantly down-
regulated in the attenuated H37Ra strain in com-
parison to the virulent H37Ra strain. Moreover, 
newly extensive identification of critical genes 
in M. tuberculosis includes the esx cluster 3 in 
the list of 600 genes essential for in vitro growth 
(16). Tb10.4 protein has conserved sequences in 
clinical isolates of M. tuberculosis (17). 
In the present study, in attempts to produce 
a vaccine against M. tuberculosis strain H37Rv, 
tb10.4 antigen was used. Tb10.4 stimulates im-
mune responses and in TB patients tb10.4 was 
even more strongly recognized than ESAT-6 (1), 
suggesting that it may be an ideal candidate to 
replace ESAT-6 (18).
The lack of diversity in TB10.4 sequence orig-
inated from 13 clinical isolates of M. tuberculo-
sis (from different geographical locations) sug-
gests that it has an important biological function 
(1). Ag-specific CD8+ T cells from infected mice 
produce several different cytokines following 
stimulation with the TB10.4 (4). Recently a zinc-
binding site has been recognized in the TB10.4 
protein involved in zinc ion acquisition (19, 20).
Desta Kassa et al. verified the immune re-
sponse against several mycobacterial antigens, 
including five classical and 64 nonclassical an-
tigens in active-pulmonary-tuberculosis (TB) 
patients. Most of the study participants (84.8%) 
responded to the TB10.4 as classical M. tubercu-
losis antigen (21).
The present study was victorious in cloning 
and expression of tb10.4 secretory protein from 
M. tuberculosis H37Rv strain. EcoRI and XbaI 
restriction enzymes were used for cloning. For 
transformation, E. coli strain JM109 was used. 
PcDNA3.1+ Vector was used to import into eu-
karyotic cells. To confirm the expression in eu-
karyotic cells, RNA extraction and RT-PCR and 
cDNA synthesis was performed.
A phagosome is a vesicle produced around 
a particle absorbed by phagocytosis in which 
pathogenic microorganisms can be destroyed 
and digested. Many mycobacteria, including M. 
tuberculosis (22, 23), manipulate the host mac-
rophage to hamper nitrous acid- comprising ly-
sosomes from fusing with phagosomes and cre-
ating mature phagolysosomes. Such immature 
phagosome maintains an environment desirable 
to the pathogens inside it (24).Since there is no 
obvious homology to known protein from other 
organisms, this protein (TB10.4) has possible im-
portant mycobacterium-specific functions, which 
may be related to the intracellular region of the 
macrophage phagosome. In this regard, expres-
sion of this molecule may be extremely up regu-
lated during intracellular growth (25).
Protective immune response against TB is 
mainly mediated through cellular immunity. In 
addition, it is dependent on activation of macro-
phages and granuloma formation. M. tuberculo-
sis in macrophage is resistant to microbicide sub-
stances. However, these microbiocide substances 
effectively destroy other phagocytic bacteria. 
This is one reason that enables M. tuberculosis 
to stop the activation of macrophage by IFN-γ 
and IL-12 cytokines. Furthermore, deficiency in 
IFN-γ, IL-12 or their receptors, increased sensi-
tivity to mycobacterium infection (26). In future, 
vaccination has a major role in the final goal of 
global eradication of tuberculosis (27, 28). Sev-
eral TB vaccine candidates have shown sufficient 
promise in pre-clinical testing in different animal 
models to certification for initial phase I [safety] 
testing in human subjects (28). 
tb10.4 DNA vaccine encoding for M. tuberculosis 
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This is a very important step for any new 
TB vaccine, and initially needs a brief study in 
healthy, PPD (Purified Protein Derivate) nega-
tive persons (usually adults). Additional Phase 
I trials may be performed on PPD+ individuals, 
children, infants, or other groups (28).
Often these trials are related to the phase IIA 
trial in which clinical samples are gathered for 
measurement of immunological response to the 
vaccine. Safety and immunogenicity are precon-
ditions for any new TB vaccine to be accepted 
further in phase III [efficacy] trials (28). The crit-
ical concerns in the clinical trials of these vac-
cines change a little depending on the vaccine 
type. For example, for the living vaccines (e.g. 
recombinant BCG strains), the main concern is 
safety. For the subunit vaccines (e.g., proteins 
or peptides), the main experiment is the devel-
opment of a safe and efficient adjuvant. For the 
DNA vaccines, the concern is effective transfer 
strategies, which ensure long-lasting protection 
(28, 29).
Construction of antigen expressing vectors 
that affecting the immunogenicity of M. tubercu-
losis, not only makes it possible to build a library 
of different antigens of this bacteria; it is pos-
sible to determine the effect of these antigens to 
stimulate the immune system and pathogenicity 
of them. In addition, these antigens can be used 
in the preparation of vaccines and designing of 
diagnostic kits.   
Conclusion
The choice of M. tuberculosis antigens for 
expression by genetic TB vaccines is a critical 
determinant of vaccine efficacy. TB10.4 is a re-
cently identified low molecular weight secreted 
M. tuberculosis protein, a member of the ESAT-6 
family. TB10.4 antigen can be recognized by T 
cells activated by BCG immunization or M. tu-
berculosis infection. Successful cloning provides 
a basis for development of new DNA vaccines 
against tuberculosis. In this study, we prepared a 
plasmid encoding tb10.4 fragment. The desired 
expression vector can be used as a vaccine in fu-
ture studies. In addition, it can be administered 
with other TB vaccines in animal models.
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